{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:52:31Z","timestamp":1787064751549,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Gilead"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Promedior"},{"name":"Incyte"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clml.2020.04.010","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T02:25:34Z","timestamp":1587435934000},"page":"e569-e578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["No Differences in Outcomes Between JAK2 V617F\u2013Positive Patients with Variant Allele Fraction\u00a0&lt; 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1451-7636","authenticated-orcid":false,"given":"Wasithep","family":"Limvorapitak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8319-5891","authenticated-orcid":false,"given":"Jeremy","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9575-0490","authenticated-orcid":false,"given":"Curtis","family":"Hughesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Foltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aly","family":"Karsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.04.010_bib1","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.010_bib2","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"17","article-title":"Introduction and Overview of the Classification of the Myeloid Neoplasms","author":"Vardiman","year":"2008"},{"key":"10.1016\/j.clml.2020.04.010_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ajh.23135","article-title":"Polycythemia vera and essential thrombocythemia: 2012 update on\u00a0diagnosis, risk stratification, and management","volume":"87","author":"Tefferi","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.010_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2020.04.010_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3324\/haematol.11653","article-title":"Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia","volume":"93","author":"Antonioli","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.04.010_bib6","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.010_bib7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2009.02.004","article-title":"Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review","volume":"124","author":"Lussana","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.clml.2020.04.010_bib8","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization\u2013essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.010_bib9","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1182\/blood-2005-12-013748","article-title":"Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation","volume":"108","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.010_bib10","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.010_bib11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.04.010_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.010_bib13","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.04.010_bib14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2141.2006.06483.x","article-title":"JAK2 (V617F) mutation in healthy individuals","volume":"136","author":"Passamonti","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.04.010_bib15","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.04.010_bib16","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.04.010_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajh.21627","article-title":"Is the JAK2V617F mutation detectable in healthy volunteers?","volume":"85","author":"Martinaud","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.010_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.04.010_bib19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1101\/gr.10.2.258","article-title":"High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR","volume":"10","author":"Germer","year":"2000","journal-title":"Genome Res"},{"key":"10.1016\/j.clml.2020.04.010_bib20","series-title":"Molecular Thermodynamics of the Stability of Natural, Sugar and Base-Modified DNA Duplexes and Its Application to the Design of Probes and Primers for Sensitive Detection of Somatic Point Mutations [dissertation]","author":"Hughesman","year":"2012"},{"key":"10.1016\/j.clml.2020.04.010_bib21","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.leu.2404292","article-title":"The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors","volume":"20","author":"Sidon","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.04.010_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.exphem.2018.09.007","article-title":"Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation","volume":"68","author":"Haunstrup","year":"2018","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2020.04.010_bib23","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.3324\/haematol.2014.107656","article-title":"Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis","volume":"99","author":"Lippert","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.04.010_bib24","doi-asserted-by":"crossref","first-page":"37239","DOI":"10.18632\/oncotarget.16744","article-title":"The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study","volume":"8","author":"Perricone","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2020.04.010_bib25","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.2019001113","article-title":"Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population","volume":"134","author":"Cordua","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.010_bib26","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.21149","article-title":"The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea","volume":"83","author":"Sirhan","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.010_bib27","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.exphem.2009.06.006","article-title":"JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera","volume":"37","author":"Carobbio","year":"2009","journal-title":"Exp Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:29Z","timestamp":1761870929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020301889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2152265020301889"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No Differences in Outcomes Between JAK2 V617F\u2013Positive Patients with Variant Allele Fraction\u00a0< 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}